分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

DSCAML1+ extracellular vesicles revealed by single-vesicle proteomics as a novel biomarker and therapeutic target in myocardial infarction

Nan Liu, Guoyue Wei, Haoran Wang, Yameng Zhang, Xipeng Sun, Fengling Lai, Yan Zheng, Keqing Hu, Tao Xu, Guohai Su, Rong Huang, Lingjun Tong

Journal:JOURNAL OF NANOBIOTECHNOLOGY

IF:15

DOI:10.1186/s12951-026-04307-3

PMID:41872860

Published:2026-03-23

research field:蛋白质组学精准医学心脏病学再生医学分子诊断学细胞外囊泡生物学

Abstract

The early and accurate diagnosis of acute myocardial infarction (AMI) remains a significant clinical challenge. To this end, we profiled the surface proteome of individual plasma extracellular vesicles (EVs) from AMI patients using single-vesicle sequencing, aiming to identify disease-associated alterations with diagnostic and therapeutic potential. Profiling the EV surface proteome across healthy controls (HC), coronary artery stenosis (CAS), and AMI revealed 21 differentially expressed proteins (DEPs), 11 of which were uniquely associated with AMI compared to HC. Notably, these included elevated levels of DSCAML1, CR1, ACE2, FN1, CDH15, and C5b‑9. EVs were subsequently stratified into 17 subpopulations, with clusters 1, 8, and 9 characterized by DSCAML1, ALCAM, and CR1, respectively, and showing the highest enrichment in AMI. We further demonstrated that plasma EVs from AMI patients (AMI-EVs) promote cardiomyocyte proliferation and endothelial cell activity in vitro, followed by the finding that the DSCAML1-enriched subpopulation (DSCAML1-EVs) enhances myocardial repair and angiogenesis both in vitro and in vivo, with mechanistic studies implicating the EREG/ERK pathway in these effects. In summary, DSCAML1-positive EVs show dual potential as both a diagnostic biomarker for AMI and a therapeutic target for improving post‑infarction prognosis, providing insight into the translational potential of EV‑based strategies in precision cardiology.

本文使用的Yeasen产品

购物车
客服
转染试用